Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Liquidia Technologies Inc

Healthcare US LQDA

38.83USD
2.96(8.25%)

Last update at 2026-03-10T20:25:00Z

Day Range

35.3038.90
LowHigh

52 Week Range

5.7116.99
LowHigh

Fundamentals

  • Previous Close 35.87
  • Market Cap938.74M
  • Volume1505999
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-91.45500M
  • Revenue TTM15.97M
  • Revenue Per Share TTM0.24
  • Gross Profit TTM 13.08M
  • Diluted EPS TTM-1.55

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -41.01500M -34.57865M -59.76277M -47.58346M -53.13586M
Minority interest - - - - -
Net income -38.36500M -29.78181M -57.49119M -46.38934M -53.13586M
Selling general administrative 32.41M 23.11M 27.37M 13.60M 8.75M
Selling and marketing expenses - - - - -
Gross profit 13.08M 9.83M 0.50M 7.26M 2.59M
Reconciled depreciation 3.65M 5.61M 3.13M 2.57M 1.54M
Ebit -38.77000M -33.79704M -59.08913M -46.82355M -34.56309M
Ebitda -37.68000M -33.76361M -58.90477M -46.20983M -33.01943M
Depreciation and amortization 1.09M 0.03M 0.18M 0.61M 1.54M
Non operating income net other - - - 0.61M 0.72M
Operating income -38.77000M -33.79704M -59.08913M -46.82355M -34.86807M
Other operating expenses 54.70M 46.65M 59.83M 54.90M 37.58M
Interest expense 2.34M 0.82M 0.86M 1.37M 18.99M
Tax provision - - - - -
Interest income 1.09M 0.03M 0.18M 0.61M 0.30M
Net interest income -1.24800M -0.78160M -0.67364M -0.75991M -18.68320M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -2.65000M -4.79684M -2.27158M -1.19412M 0.72M
Total revenue 15.94M 12.85M 0.74M 8.07M 2.71M
Total operating expenses 51.85M 43.63M 59.59M 54.09M 37.45M
Cost of revenue 2.86M 3.02M 0.24M 0.81M 0.12M
Total other income expense net -2.24500M -0.78160M -0.67364M -0.75991M 0.42M
Discontinued operations - - - - -
Net income from continuing ops -41.01500M -34.57865M -59.76277M -47.58346M -53.13586M
Net income applicable to common shares -41.01500M -34.57865M -59.76277M -47.58346M -53.13586M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 120.43M 129.20M 93.73M 99.53M 68.84M
Intangible assets 3.43M 3.73M 4.39M 5.53M -
Earning assets - - - - -
Other current assets 2.16M 1.51M 0.79M 0.75M 0.59M
Total liab 73.14M 38.78M 28.46M 28.45M 33.89M
Total stockholder equity 47.29M -350.59600M -309.58087M -275.00222M 34.95M
Deferred long term liab - 8.60M 10.14M 12.79M -
Other current liab 16.02M 5.52M 5.17M 1.77M 5.98M
Common stock 0.07M 0.06M 0.05M 0.04M 0.03M
Capital stock 0.07M 0.06M 0.05M 0.04M 0.03M
Retained earnings -429.09800M -350.59600M -309.58087M -275.00222M -215.23945M
Other liab - 6.59M 6.14M 1.15M -
Good will 3.90M 3.90M 3.90M 3.90M -
Other assets 0.00000M 129.20M 16.73M 17.22M 0.38M
Cash 83.68M 93.28M 57.49M 65.32M 55.80M
Cash and equivalents - - - - -
Total current liabilities 18.55M 8.80M 7.33M 11.74M 16.87M
Current deferred revenue - - - 4.65M -
Net debt -80.17600M -68.82000M -41.41502M -48.17441M -31.37992M
Short term debt 1.14M 1.08M 1.09M 1.59M 7.40M
Short long term debt - - - - 5.59M
Short long term debt total 3.50M 24.46M 16.08M 17.14M 24.42M
Other stockholder equity 476.32M -0.06400M -0.05229M -0.04334M 250.16M
Property plant equipment - 6.25M 7.43M 9.45M 12.08M
Total current assets 89.90M 99.81M 61.28M 66.07M 56.39M
Long term investments - - - - -
Net tangible assets - 82.79M 56.97M 61.65M 34.95M
Short term investments - - - - -
Net receivables 4.06M 5.02M 2.99M - 0.00000M
Long term debt - 19.88M 10.41M 10.29M 10.29M
Inventory 0.00000M - - - -
Accounts payable 1.40M 2.20M 1.07M 3.73M 3.50M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -11.33311M
Additional paid in capital - - - - -
Common stock total equity - - - 0.04M 0.03M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -215.23945M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 14.92M 15.51M 16.73M 14.57M 0.38M
Deferred long term asset charges - - - - -
Non current assets total 30.53M 29.39M 32.45M 33.46M 12.46M
Capital lease obligations 3.50M 4.58M 5.67M 6.85M 8.54M
Long term debt total - - - - 11.35M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.58700M -0.10722M 0.25M -1.85010M -0.87094M
Change to liabilities 0.81M -7.55884M -0.29716M 0.83M -2.90317M
Total cashflows from investing activities -0.58700M -0.10722M 0.25M -1.85010M -0.87094M
Net borrowings 8.96M -0.41984M -6.76942M 4.00M -1.42528M
Total cash from financing activities 64.96M 26.32M 63.42M 66.39M 68.82M
Change to operating activities -0.94500M -1.83288M -1.41448M 0.55M 1.85M
Net income -41.01500M -34.57865M -59.76277M -47.58346M -53.13586M
Change in cash 35.79M -7.82255M 9.52M 16.26M 36.12M
Begin period cash flow 57.49M 65.32M 55.80M 39.53M 3.42M
End period cash flow 93.28M 57.49M 65.32M 55.80M 39.53M
Total cash from operating activities -28.58800M -34.03566M -54.14451M -48.28267M -31.83054M
Issuance of capital stock 54.46M 21.71M 71.23M 63.04M 72.43M
Depreciation 3.65M 5.61M 3.13M 2.57M 1.54M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - -1.73015M - - -1346.98700M
Change to account receivables -2.02700M -2.98972M -2.98972M 0.27M 1349.62M
Sale purchase of stock - - - 62.43M 72.76M
Other cashflows from financing activities 21.31M 15.44M -1.03929M 4.39M 34.51M
Change to netincome 10.94M 7.31M 4.14M 3.38M 1.92M
Capital expenditures 0.59M 0.11M 0.75M 1.85M 0.87M
Change receivables - - - 0.27M -
Cash flows other operating - - - -7.83275M -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 16.26M -
Change in working capital -2.15800M -12.38144M -1.71165M -6.95075M 0.29M
Stock based compensation 9.30M 6.75M 3.95M 3.38M 2.20M
Other non cash items 1.64M 0.52M 0.24M 0.30M 17.69M
Free cash flow -29.18000M -34.14288M -54.89659M -50.13277M -32.70148M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
LQDA
Liquidia Technologies Inc		 2.96 8.25% 38.83 - - 60.65 22.43 56.06 -13.9957
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Liquidia Technologies Inc

419 Davis Drive, Morrisville, NC, United States, 27560

Key Executives

Name Title Year Born
Dr. Roger A. Jeffs Ph.D. CEO & Director 1962
Mr. Robert A. Lippe Chief Operations Officer 1965
Dr. Tushar Shah M.D. Sr. VP of Product Devel. 1961
Mr. William R. Kenan Jr. Co-Founder NA
Dr. Ginger Denison Co-Founder NA
Mr. Michael Kaseta Chief Financial Officer 1976
Jennifer Almond Director of Investor Relations & Corp. Communications NA
Mr. Russell Schundler Gen. Counsel & Corp. Sec. 1975
Mr. Jason Adair Sr. VP of Corp. Devel. & Strategy 1974
Ms. Celia Reyes-Hoke VP of People & Culture NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.